Diagnosis and management of chronic myeloid leukemia: A survey of American and European practice patterns

Cancer

Volumn 109, Issue 7, 2007, Pages 1365-1375

  Kantarjian, Hagop M ^a   Cortes, Jorge ^a   Guilhot, François ^b   Hochhaus, Andreas ^c   Baccarani, Michele ^d   Lokey, Lee ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Oncology Network Europe   (United States)

Author keywords

BCR ABL mutation; Clinical practice; CML; Dasatinib; Imatinib; Molecular monitoring; Survey

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ANEMIA; ARTICLE; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DECISION MAKING; DIARRHEA; DRUG MEGADOSE; DRUG WITHDRAWAL; EUROPE; FATIGUE; FEMALE; FLUID RETENTION; GENE MUTATION; HUMAN; INTERNET; LIVER DYSFUNCTION; LOW DRUG DOSE; MEDICAL PRACTICE; MULTIPLE CHOICE TEST; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PERICARDIAL EFFUSION; PERICARDITIS; PERIORBITAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; SELF REPORT; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; VOMITING; WEIGHT GAIN;

AGED; EUROPE; FEMALE; FUSION PROTEINS, BCR-ABL; HEALTH SURVEYS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUESTIONNAIRES; UNITED STATES;

EID: 33947496833     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22523     Document Type: Article

References (28)

1. Guilhot F, Chastang C, Michallet M, et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172-183.
3. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
5. Guilhot F, Larson R, O'Brien S, Druker B, on behalf of IRIS Study Group. Long-term benefits of imatinib for patients newly diagnosed with chronic myeloid leukemia in chronic phase: the 5-year update from the IRIS study. Haematologica. 2006;91:170. Abstract 466.
6. Deininger MW. Management of early stage disease. Hematology (Am Soc Hematol Educ Program). 2005;1:174-182.
7. Druker B, Guilhot F, O'Brien S, Larson R. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:338s. Abstract 6506.
8. Mauro M, Deininger M. Chronic myeloid leukemia in 2006: a perspective. Hematologica. 2006;91:152-158.
9. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 2006;20:29-41.
10. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
11. Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 2005;19:507-512.
12. Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia. 2003;17:2392-2400.
13. Paschka P, Muller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687-1694.
14. Faderl S, Hochhaus A, Hughes T. Monitoring of minimal residual disease in chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:657-670,ix-x.
15. NCCN. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia version 1. Jenkintown, PA: NCCN;2006.
16. Novartis. Gleevec (imatinib mesylate) prescribing information. Hanover, NJ: Novartis; 2005.
17. Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant. 2006;12:795-807.
18. Aoki E, Kantarjian H, O'Brien S, et al. High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:345s. Abstract 6535.
19. Coutre S, Martinelli G, Dombret H, et al. Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): the CA180015 'START-L' study. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:344s. Abstract 6528.
20. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013 'START-C' study. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:339s. Abstract 6508.
21. Talpaz M, Apperley J, Kim D, et al. Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: results of the CA180005 'START-A' study. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:343s. Abstract 6526.
22. Shah N, Rousselot P, Pasquini R, et al. Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:338s. Abstract 6507.
23. Cortes J, Kim D, Rosti G, et al. Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): results of the CA180006 'START-B' study [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:344s. Abstract 6529.
24. Giles F, Larson R, Le Coutre P, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:346s. Abstract 6536.
25. Le Coutre P, Ottman O, Gattermann N, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:344s. Abstract 6531.
26. Kantarjian H, Gattermann N, O'Brien S, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) [abstract]. J Clin Oncol (ASCO Annual Meeting Proc). 2006;24:345s. Abstract 6534.
27. Druker B, Gathmann I, Bolton A, Larson R, on behalf of the IRIS (International Randomized IFN vs. STI571) study group. Probability and impact of obtaining a cytogenetic response to Imatinib as initial therapy for chronic myeloid leukemia in chronic phase. Blood. 2003;102:182a. Abstract 634.
28. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.